Literature DB >> 28447061

RAINFALL before RAINBOW-an illusion or reality?

Kohei Shitara1.   

Abstract

Year:  2017        PMID： 28447061      PMCID： PMC5388627          DOI： 10.21037/tgh.2017.03.04

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  14 in total

1.  Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Authors:  J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

2.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

Authors:  Atsushi Ohtsu; Manish A Shah; Eric Van Cutsem; Sun Young Rha; Akira Sawaki; Sook Ryun Park; Ho Yeong Lim; Yasuhide Yamada; Jian Wu; Bernd Langer; Michal Starnawski; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

3.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

4.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

5.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

6.  Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

Authors:  H H Yoon; J C Bendell; F S Braiteh; I Firdaus; P A Philip; A L Cohn; N Lewis; D M Anderson; E Arrowsmith; J D Schwartz; L Gao; Y Hsu; Y Xu; D Ferry; S R Alberts; Z A Wainberg
Journal:  Ann Oncol       Date:  2016-10-20       Impact factor: 51.769

Review 7.  Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.

Authors:  L H McCormick Matthews; F Noble; J Tod; E Jaynes; S Harris; J N Primrose; C Ottensmeier; G J Thomas; T J Underwood
Journal:  Br J Cancer       Date:  2015-06-25       Impact factor: 7.640

8.  Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.

Authors:  Manish A Shah; Yung-Jue Bang; Florian Lordick; Maria Alsina; Meng Chen; Stephen P Hack; Jean Marie Bruey; Dustin Smith; Ian McCaffery; David S Shames; See Phan; David Cunningham
Journal:  JAMA Oncol       Date:  2017-05-01       Impact factor: 31.777

9.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.

Authors:  Tom Waddell; Ian Chau; David Cunningham; David Gonzalez; Alicia Frances Clare Okines; Alicia Frances; Clare Okines; Andrew Wotherspoon; Claire Saffery; Gary Middleton; Jonathan Wadsley; David Ferry; Wasat Mansoor; Tom Crosby; Fareeda Coxon; David Smith; Justin Waters; Timothy Iveson; Stephen Falk; Sarah Slater; Clare Peckitt; Yolanda Barbachano
Journal:  Lancet Oncol       Date:  2013-04-15       Impact factor: 41.316

10.  Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.

Authors:  Charles S Fuchs; Josep Tabernero; Jiří Tomášek; Ian Chau; Bohuslav Melichar; Howard Safran; Mustapha A Tehfe; Dumitru Filip; Eldar Topuzov; Luis Schlittler; Anghel Adrian Udrea; William Campbell; Stephen Brincat; Michael Emig; Symantha A Melemed; Rebecca R Hozak; David Ferry; C William Caldwell; Jaffer A Ajani
Journal:  Br J Cancer       Date:  2016-09-13       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.